Exploring Opportunities, Legal Considerations, and Pharmacy Readiness

PCAC advises the United States Food and Drug Administration (FDA) on pharmacy compounding issues. The talks will assist the agency in decision-making by taking into account the information given, in addition to other regulatory requirements of the substance. Pharmacy practitioners have been considerably concerned about the acceptance of PCAC peptide, although the committee’s recommendation does not necessarily entail FDA approval of the chemical.

Pharmacies interested in these advancements need to know what the FDA’s current requirements are for compounding peptides. Not every peptide can be compounded since various restrictions apply to each individual product that is compounded. If a peptide is addressed at an advisory committee meeting, pharmacists should be aware that the substance is not automatically eligible for compounding until the regulations for that particular peptide are amended.

The topic also brings up problems of future peptide compounding in an independent pharmacy. For the majority of pharmacies, any expected changes would entail consequences such as modifications to the plans of services given, the procurement of ingredients, personnel training, and quality control systems. All decisions on services linked to peptides, however, will be made based on the present law, not on what the FDA could do next. By keeping up to date, pharmacists will be better placed to plan for such changes while still meeting present legal duties.

Section 503A of the FDCA sets forth the standards for conventional pharmacy compounding. The 503A peptide compounding under this legislation should be evaluated in connection with the prescription, bulk medication substances, and other regulatory requirements. Popularity or discussion in an advisory panel meeting does not equate to fitness for compounding. It is the duty of pharmacists to determine the legality of the use of individual preparations through different statutory regulations.

For the time being, the biggest takeaway is that an interest in peptides is not the same as modifications to the legislation. The PCAC conference may be part of a broader discussion on the future of these compounds, but any substantive adjustments would have to be done through the appropriate FDA regulatory processes. “Independent pharmacies are going to have to stay current with the changing regulations and what each substance requires, so that’s going to be important in the future.